Analyzing the Future of Hereditary Angioedema Therapeutics Market Dynamics 2025-2034: Growth Rate, Trends, and Major Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the hereditary angioedema therapeutics market size evolved in recent years?
The market size for therapeutics dealing with hereditary angioedema has experienced a swift expansion in recent times. The market, which was worth $6.68 billion in 2024, is projected to increase to $7.84 billion in 2025, indicating a compound annual growth rate (CAGR) of 17.3%. Factors contributing to the growth during the historical period include bettered diagnosis and awareness, broadened access to treatments, research and development projects, patient advocacy and education, and regulatory green signals.
What are the predictions for the hereditary angioedema therapeutics market size in the coming years?
The market for therapeutics related to hereditary angioedema is predicted to surge rapidly in the coming years, growing to “$16.11 billion by 2029 with a compound annual growth rate (CAGR) of 19.7%. The growth for the projected period can be linked to improvements in targeted therapies, the expansion of the global market, progress in gene therapy, the popularity of personalized medicine, and collaborative efforts in research and treatment. Key trends in the projected period encompass global access initiatives, research on health economic outcomes, strategies for early intervention, and therapeutics for pediatric HAE.
Get your hereditary angioedema therapeutics market report here!
What key factors are fueling the growth of the hereditary angioedema therapeutics market?
The increasing incidence of hereditary angioedema is projected to fuel the expansion of the hereditary angioedema market in the future. Hereditary angioedema, or HAE, is a rare inherited condition that is characterised by recurring severe swelling incidents of the skin and mucus membranes, attributable to an accumulation of excess fluid known as edema. This swelling can present itself anywhere on the body, such as the hands, feet, face, intestines, and airways. To illustrate, in June 2022, the online health information provider, Rare Disease Advisor, stated that globally, hereditary angioedema affects one in every 50,000 individuals, with prevalence estimates varying from 1:10,000 to 1:150,000. Each year, HAE episodes result in between 15,000 to 30,000 emergency room visits in the US. In 5.8% of HAE cases, the average diagnosis time span was 0 to 6 months, while in another 5.8% of cases, the diagnosis took over 10 years. Hence, the escalating incidence of hereditary angioedema is pushing the hereditary angioedema market’s growth forward.
How is the global hereditary angioedema therapeutics market divided into key segments?
The hereditary angioedema therapeutics market covered in this report is segmented –
1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes
2) By Route of Administration: Intravenous, Subcutaneous, Oral
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
4) By Application: Prophylaxis, On-demand
Subsegments:
1) By C1 Esterase Inhibitor: Plasma-Derived, Recombinant
2) By Selective Bradykinin B2 Receptor Antagonist: Icatibant
3) By Kallikrein Inhibitor: Ecallantide, Lanadelumab
4) By Other Drug Classes: Emerging Therapies
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10810&type=smp
Who are the key firms paving the way for growth in the hereditary angioedema therapeutics market?
Major companies operating in the hereditary angioedema therapeutics market include Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., Adverum Biotechnologies Inc., Arrowhead Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., CENTOGENE N.V., GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., AbbVie Inc., Incyte Corporation, BioMarin Pharmaceutical Inc., Dyax Corp., Salix Pharmaceuticals Inc., Pharvaris N.V., Innovent Biologics Inc., AstraZeneca plc, BeiGene Ltd., Jiangsu HenGrui Medicine Co. Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG ., Exelixis Inc., Lev Pharmaceuticals Inc., Kedrion Biopharma Inc., Pharos Pharmaceuticals Inc.
Which trends are expected to transform the hereditary angioedema therapeutics market?
A significant trend that is increasingly gaining traction in the hereditary angioedema therapeutics market is the innovation of products. The dominant players in this market are investing in groundbreaking products like ligand-conjugated (LICA) investigational antisense medicine and gene therapy to maintain their market stake. For instance, in March 2023, the US-based clinical-stage biotechnology enterprise, Intellia Therapeutics, introduced Investigational New Drug (IND) NTLA-2002, duly approved by the United States Food and Drug Administration for treating hereditary angioedema. This has allowed the company to extend its ongoing Phase 1/2 trial to cover the US in the worldwide Phase 2 aspect. Upon administering a single dose of therapy, the target gene, kallikrein B1 (KLKB1), will be permanently deactivated, which will decrease plasma kallikrein protein activity and inhibit HAE attacks in the long term. NTLA-2002 is a potential candidate for in vivo genome editing.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10810
What regions are contributing significantly to the growth of the hereditary angioedema therapeutics market?
North America was the largest region in the global hereditary angioedema therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Similar Reports By The Business Research Company:
Online Therapy Services Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/online-therapy-services-global-market-report
Vitamin D Therapy Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/vitamin-d-therapy-global-market-report
Targeted Therapy Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
